Page 6 - Nasdaq Axsm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq axsm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Axsm Today - Breaking & Trending Today

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Recommendation of "Moderate Buy" by Brokerages

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 year target price among […] ....

United States , William Blair , Blackrock Inc , Vanguard Group Inc , Cantor Fitzgerald , Axsome Therapeutics Inc , Axsome Therapeutics Company Profile , Axsome Therapeutics , Get Free Report , Marketbeat Ratings , Get Free , Axsome Therapeutics Daily , Nasdaq Axsm ,

Mizuho Reiterates Buy Rating for Axsome Therapeutics (NASDAQ:AXSM)

Mizuho reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $100.00 price target on the stock. Several other equities research analysts have also commented on AXSM. William Blair reiterated an outperform rating on shares of Axsome Therapeutics […] ....

United States , William Blair , Harbour Investments Inc , Axsome Therapeutics Company Profile , Axsome Therapeutics Inc , Morgan Stanley , Tower Research Capital , China Universal Asset Management Co , Cantor Fitzgerald , Axsome Therapeutics , Free Report , Moderate Buy , Get Free Report , Financial Advisors , Universal Asset Management , Research Capital , Dark Forest Capital Management , Axsome Therapeutics Daily , Nasdaq Axsm , Reiterated Rating ,

Axsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2023 Earnings of ($1.31) Per Share, Zacks Research Forecasts

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Equities research analysts at Zacks Research lowered their Q3 2023 earnings per share estimates for Axsome Therapeutics in a research note issued to investors on Monday, August 21st. Zacks Research analyst K. Shah now anticipates that the company will earn ($1.31) per share for the quarter, down […] ....

United States , Piper Sandler , Axsome Therapeutics Inc , Zacks Research , China Universal Asset Management Co , Victory Capital Management Inc , Ameritas Investment Partners Inc , Morgan Stanley , Tower Research Capital , Axsome Therapeutics Company Profile , Capital Management , Axsome Therapeutics , Free Report , Axsome Therapeutic , Therapeutics Stock Down , Universal Asset Management , Investment Partners , Research Capital , Victory Capital Management , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Earnings Estimates ,

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $100.00

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price lifted by Mizuho from $95.00 to $100.00 in a research report released on Friday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. Several other research analysts also recently weighed in on AXSM. HC Wainwright dropped their target price on shares […] ....

United States , Piper Sandler , Axsome Therapeutics Inc , Boxer Capital , Vr Adviser , Axsome Therapeutics , Free Report , Marketbeat Ratings , Moderate Buy , Deep Track Capital , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Boost Price Target ,

Axsome Therapeutics (NASDAQ:AXSM) Given New $180.00 Price Target at HC Wainwright

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target lowered by HC Wainwright from $190.00 to $180.00 in a research report released on Tuesday, Marketbeat reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2023 earnings at ($1.12) EPS, Q4 2023 earnings at […] ....

United States , Piper Sandler , William Blair , China Universal Asset Management Co , Axsome Therapeutics Company Profile , Pricet Rowe Associates Inc , Victory Capital Management Inc , Morgan Stanley , Axsome Therapeutics Inc , Capital Management , Ameritas Investment Partners Inc , Axsome Therapeutics , Free Report , Moderate Buy , Therapeutics Stock Down , Universal Asset Management , Investment Partners , Pricet Rowe Associates , Get Free Report , Axsome Therapeutics Daily , Nasdaq Axsm , Lower Price Target , Hc Wainwright ,